Clinical Trial Update: Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update on selegiline for excessive daytime sleepiness in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Selegiline (selegiline)

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Parkinson Disease | Phase 4 | Status: COMPLETED